Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C46H80N2O13.H3O4P |
| Molecular Weight | 967.1282 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 19 / 19 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OP(O)(O)=O.CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN3C[C@@H](C)C[C@@H](C)C3)C[C@@H](C)C(=O)\C=C\C(C)=C\[C@@H]1CO[C@@H]4O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]4OC
InChI
InChIKey=NESIVXZOSKKUDP-ARVJLQODSA-N
InChI=1S/C46H80N2O13.H3O4P/c1-13-36-33(24-57-46-44(56-12)43(55-11)40(53)31(8)59-46)19-25(2)14-15-34(49)28(5)20-32(16-17-48-22-26(3)18-27(4)23-48)42(29(6)35(50)21-37(51)60-36)61-45-41(54)38(47(9)10)39(52)30(7)58-45;1-5(2,3)4/h14-15,19,26-33,35-36,38-46,50,52-54H,13,16-18,20-24H2,1-12H3;(H3,1,2,3,4)/b15-14+,25-19+;/t26-,27+,28-,29+,30-,31-,32+,33-,35-,36-,38+,39-,40-,41-,42-,43-,44-,45+,46-;/m1./s1
DescriptionSources: http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm115928.pdfCurator's Comment: description was created based on several sources, including
http://www.fao.org/docrep/W4601E/w4601e0e.htm
http://www.merckvetmanual.com/mvm/pharmacology/antibacterial_agents/macrolides.html
Sources: http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm115928.pdf
Curator's Comment: description was created based on several sources, including
http://www.fao.org/docrep/W4601E/w4601e0e.htm
http://www.merckvetmanual.com/mvm/pharmacology/antibacterial_agents/macrolides.html
Tilmicosin is a macrolide antibiotic was prepared by chemical modifications of desmycosin, and is used in veterinary. It is recommended for treatment and prevention of pneumonia in cattle, sheep and pigs, associated with Pasteurella haemolytica, P. multocida, Actinobacillus pleuropneumoniae, mycoplasma species and other microorganisms found sensitive to this compound. Tilmicosin belongs to 16-membered ring group of class macrolides. The antimicrobial mechanism seems to be the same for all of the macrolides. They interfere with protein synthesis by reversibly binding to the 50S subunit of the ribosome. They appear to bind at the donor site, thus preventing the translocation necessary to keep the peptide chain growing. The effect is essentially confined to rapidly dividing bacteria and mycoplasmas. Macrolides are regarded as being bacteriostatic but demonstrate bactericidal activity at high concentrations.
Originator
Sources: http://www.ncbi.nlm.nih.gov/pubmed/3570967
Curator's Comment: A new macrolide antibiotic, EL-870, 20-deoxo-20-(3,5-dimethylpiperidin-1-yl)desmycosin, has been prepared by chemical modification of desmycosin
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2363135 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | MICOTIL 300 Approved UseFor the treatment of bovine respiratory disease (BRD) and ovine respiratory disease (ORD) associated with Mannheimia (Pasteurella) haemolytica. For the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia (Pasteurella) haemolytica. Launch Date2005 |
|||
| Curative | MICOTIL 300 Approved UseFor the treatment of bovine respiratory disease (BRD) and ovine respiratory disease (ORD) associated with Mannheimia (Pasteurella) haemolytica. For the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia (Pasteurella) haemolytica. Launch Date2005 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Concentrations of tilmicosin in mammary gland secretions of dairy cows following subcutaneous administration of one or two doses of an experimental preparation of tilmicosin and its efficacy against intramammary infections caused by Staphylococcus aureus. | 2016-09 |
Patents
Sample Use Guides
for animasl only: 10 mg/kg body weight (BW)(1.5 mL per 100 lb BW), administered once
Route of Administration:
Other
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/8787526
The MIC95 of TILMICOSIN for the Actinobacillus pleuropneumoniae isolates was 6.25 ug/mL while for the Pasteurella multocida isolates it was 12.5 ug/mL
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C261
Created by
admin on Mon Mar 31 18:01:12 GMT 2025 , Edited by admin on Mon Mar 31 18:01:12 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
EE-26
Created by
admin on Mon Mar 31 18:01:12 GMT 2025 , Edited by admin on Mon Mar 31 18:01:12 GMT 2025
|
PRIMARY | |||
|
100000181047
Created by
admin on Mon Mar 31 18:01:12 GMT 2025 , Edited by admin on Mon Mar 31 18:01:12 GMT 2025
|
PRIMARY | |||
|
5282522
Created by
admin on Mon Mar 31 18:01:12 GMT 2025 , Edited by admin on Mon Mar 31 18:01:12 GMT 2025
|
PRIMARY | |||
|
SUB194841
Created by
admin on Mon Mar 31 18:01:12 GMT 2025 , Edited by admin on Mon Mar 31 18:01:12 GMT 2025
|
PRIMARY | |||
|
DTXSID201019820
Created by
admin on Mon Mar 31 18:01:12 GMT 2025 , Edited by admin on Mon Mar 31 18:01:12 GMT 2025
|
PRIMARY | |||
|
SMH7U1S683
Created by
admin on Mon Mar 31 18:01:12 GMT 2025 , Edited by admin on Mon Mar 31 18:01:12 GMT 2025
|
PRIMARY | |||
|
C84214
Created by
admin on Mon Mar 31 18:01:12 GMT 2025 , Edited by admin on Mon Mar 31 18:01:12 GMT 2025
|
PRIMARY | |||
|
CHEMBL1908333
Created by
admin on Mon Mar 31 18:01:12 GMT 2025 , Edited by admin on Mon Mar 31 18:01:12 GMT 2025
|
PRIMARY | |||
|
SMH7U1S683
Created by
admin on Mon Mar 31 18:01:12 GMT 2025 , Edited by admin on Mon Mar 31 18:01:12 GMT 2025
|
PRIMARY | |||
|
1294593
Created by
admin on Mon Mar 31 18:01:12 GMT 2025 , Edited by admin on Mon Mar 31 18:01:12 GMT 2025
|
PRIMARY | RxNorm | ||
|
137330-13-3
Created by
admin on Mon Mar 31 18:01:12 GMT 2025 , Edited by admin on Mon Mar 31 18:01:12 GMT 2025
|
PRIMARY | |||
|
DBSALT001661
Created by
admin on Mon Mar 31 18:01:12 GMT 2025 , Edited by admin on Mon Mar 31 18:01:12 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD